These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3513634)

  • 1. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder.
    Gardner DL; Cowdry RW
    Am J Psychiatry; 1986 Apr; 143(4):519-22. PubMed ID: 3513634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alprazolam-induced dyscontrol in borderline personality disorder.
    Gardner DL; Cowdry RW
    Am J Psychiatry; 1985 Jan; 142(1):98-100. PubMed ID: 2857071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.
    Cowdry RW; Gardner DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):111-9. PubMed ID: 3276280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sedative or antimanic effects of carbamazepine and treatment of behavioral dyscontrol.
    Greenberg WM
    Am J Psychiatry; 1986 Nov; 143(11):1486-7. PubMed ID: 3535545
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of melancholia during carbamazepine treatment in borderline personality disorder.
    Gardner DL; Cowdry RW
    J Clin Psychopharmacol; 1986 Aug; 6(4):236-9. PubMed ID: 3525615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacology of borderline personality disorder: a review.
    Cowdry RW
    J Clin Psychiatry; 1987 Aug; 48 Suppl():15-25. PubMed ID: 2886493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of self-mutilation in a patient with borderline personality during risperidone therapy.
    Khouzam HR; Donnelly NJ
    J Nerv Ment Dis; 1997 May; 185(5):348-9. PubMed ID: 9171814
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical effects of amitriptyline on borderline patients.
    Soloff PH; George A; Nathan RS; Schulz PM; Perel JM
    Am J Psychiatry; 1986 Dec; 143(12):1603-5. PubMed ID: 3538914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral dyscontrol in borderline patients treated with amitriptyline.
    Soloff PH; George A; Nathan RS; Schulz PM; Perel JM
    Psychopharmacol Bull; 1987; 23(1):177-81. PubMed ID: 3602316
    [No Abstract]   [Full Text] [Related]  

  • 11. Recurrent suicide attempts, self-mutilation, and binge/purge behavior: a case report.
    Schinagle M
    Harv Rev Psychiatry; 2002; 10(6):353-63. PubMed ID: 12485981
    [No Abstract]   [Full Text] [Related]  

  • 12. A trial of carbamazepine in borderline personality disorder.
    de la Fuente JM; Lotstra F
    Eur Neuropsychopharmacol; 1994 Dec; 4(4):479-86. PubMed ID: 7894258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study.
    Zanarini MC; Frankenburg FR; Reich DB; Silk KR; Hudson JI; McSweeney LB
    Am J Psychiatry; 2007 Jun; 164(6):929-35. PubMed ID: 17541053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials.
    Ingenhoven T; Lafay P; Rinne T; Passchier J; Duivenvoorden H
    J Clin Psychiatry; 2010 Jan; 71(1):14-25. PubMed ID: 19778496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxcarbazepine for self-mutilating bulimic patients.
    Cordás TA; Tavares H; Calderoni DM; Stump GV; Ribeiro RB
    Int J Neuropsychopharmacol; 2006 Dec; 9(6):769-71. PubMed ID: 16893478
    [No Abstract]   [Full Text] [Related]  

  • 16. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
    Nickel MK; Muehlbacher M; Nickel C; Kettler C; Pedrosa Gil F; Bachler E; Buschmann W; Rother N; Fartacek R; Egger C; Anvar J; Rother WK; Loew TH; Kaplan P
    Am J Psychiatry; 2006 May; 163(5):833-8. PubMed ID: 16648324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder.
    Bertsch K; Gamer M; Schmidt B; Schmidinger I; Walther S; Kästel T; Schnell K; Büchel C; Domes G; Herpertz SC
    Am J Psychiatry; 2013 Oct; 170(10):1169-77. PubMed ID: 23982273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary trial of fluoxetine in refractory borderline patients.
    Cornelius JR; Soloff PH; Perel JM; Ulrich RF
    J Clin Psychopharmacol; 1991 Apr; 11(2):116-20. PubMed ID: 2056138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suicidal and parasuicidal behavior in borderline personality disorder.
    Gardner DL; Cowdry RW
    Psychiatr Clin North Am; 1985 Jun; 8(2):389-403. PubMed ID: 3895199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-mutilation and suicide attempts: relationships to bipolar disorder, borderline personality disorder, temperament and character.
    Joyce PR; Light KJ; Rowe SL; Cloninger CR; Kennedy MA
    Aust N Z J Psychiatry; 2010 Mar; 44(3):250-7. PubMed ID: 20180727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.